Australia's most trusted
source of pharma news
Posted 14 August 2025 PM
Echo Therapeutics is working hard to maintain supply of Pegasys, the hepatitis treatment it assumed sponsorship of from Roche in 2022.
The Sydney-based pharmaceutical distribution company started in 2018 by former Roche Director, Jude D’Silva, has notified the TGA that it expects shortages of Pegasys injection pre-filled syringes in both 180 and 135 microgram strengths to continue until December 2025, citing “changes in manufacturing sites and supply constraints due to global shortages”.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.